Genoway SA
PAR:ALGEN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.36
4.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genoway SA
Genoway SA
Net Income (Common)
Genoway SA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genoway SA
PAR:ALGEN
|
Net Income (Common)
€1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
20%
|
|
|
Valneva SE
PAR:VLA
|
Net Income (Common)
€17.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Income (Common)
€22.3m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Net Income (Common)
-€104.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Net Income (Common)
€6.6m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Net Income (Common)
€46m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genoway SA
Glance View
genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
See Also
What is Genoway SA's Net Income (Common)?
Net Income (Common)
1.3m
EUR
Based on the financial report for Jun 30, 2024, Genoway SA's Net Income (Common) amounts to 1.3m EUR.
What is Genoway SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
20%
Over the last year, the Net Income (Common) growth was -21%.
You don't have any saved screeners yet
